Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 24, 2025
Daily News
October 24, 2025
- MHLW Outlines 4 Key Themes for 2026 Reform, Eyes OTC-Like Meds, CEA for Efficiency
October 24, 2025
- Teijin Licenses RA Drug Candidate to UK’s Elevara
October 24, 2025
- Celltrion Files Biosimilar without Japanese Clinical Data, More Firms Might Follow
October 24, 2025
- Earnings Season Kicks Off, Off-Year Revision Impact in Spotlight
October 24, 2025
- JMA Renews Opposition to Insurance Review for OTC-Like Drugs
October 24, 2025
- Santen Rolls Out Glaucoma Drug Setaneo in Japan
October 24, 2025
- FDA Again Rejects Mitsubishi Tanabe’s Parkinson’s Drug
October 24, 2025
- Kissei’s Linzagolix Approved for Uterine Fibroids in Taiwan
October 24, 2025
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…